A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan to ACT-385781A in Patients With Pulmonary Arterial Hypertension

Trial Profile

A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan to ACT-385781A in Patients With Pulmonary Arterial Hypertension

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Jan 2015

At a glance

  • Drugs Epoprostenol (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Pharmacodynamics; Registrational
  • Acronyms EPITOME-2
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 18 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top